Esposito, S.; Fainardi, V.; Capra, M.E.; Aricò, M.; Lanzoni, A.; Campana, B.R.; Niceforo, M.; Neglia, C.; Valletta, E.; Biasucci, G.;
et al. Acceptance of Nirsevimab for the Prevention of Respiratory Syncytial Virus Infection in Neonates: A Cross-Sectional Survey in Emilia-Romagna, Italy. Vaccines 2025, 13, 896.
https://doi.org/10.3390/vaccines13090896
AMA Style
Esposito S, Fainardi V, Capra ME, Aricò M, Lanzoni A, Campana BR, Niceforo M, Neglia C, Valletta E, Biasucci G,
et al. Acceptance of Nirsevimab for the Prevention of Respiratory Syncytial Virus Infection in Neonates: A Cross-Sectional Survey in Emilia-Romagna, Italy. Vaccines. 2025; 13(9):896.
https://doi.org/10.3390/vaccines13090896
Chicago/Turabian Style
Esposito, Susanna, Valentina Fainardi, Maria Elena Capra, Melodie Aricò, Angela Lanzoni, Beatrice Rita Campana, Marta Niceforo, Cosimo Neglia, Enrico Valletta, Giacomo Biasucci,
and et al. 2025. "Acceptance of Nirsevimab for the Prevention of Respiratory Syncytial Virus Infection in Neonates: A Cross-Sectional Survey in Emilia-Romagna, Italy" Vaccines 13, no. 9: 896.
https://doi.org/10.3390/vaccines13090896
APA Style
Esposito, S., Fainardi, V., Capra, M. E., Aricò, M., Lanzoni, A., Campana, B. R., Niceforo, M., Neglia, C., Valletta, E., Biasucci, G., & Perrone, S.
(2025). Acceptance of Nirsevimab for the Prevention of Respiratory Syncytial Virus Infection in Neonates: A Cross-Sectional Survey in Emilia-Romagna, Italy. Vaccines, 13(9), 896.
https://doi.org/10.3390/vaccines13090896
